Aktieanalys

Moberg Pharma Q3’23: National approvals as expected - Redeye

Redeye 07 Nov 2023 09:37

Redeye saw a report that came in more or less as expected. There were as expected no sales in the quarter and costs were more or less in our expectations. The main events in the quarter are the national approvals in another ten countries. However, this was expected as the recommendation in the EU was strong. The approvals are positive as they prove that the process is going forward and that there seem to be no real issues. More approvals will come in the coming quarters. The most important national approvals in the short term are Sweden and Norway, as these are the countries where sales could start in the first half of 2024e.

Länk till analysen i sin helhet: https://www.redeye.se/research/955942/moberg-pharma-q323-national-approvals-as-expected?utm_source=finwire&utm_medium=RSS

Börskollens app – Högt betyg ⭐⭐⭐⭐⭐ och 250.000 nedladdningar

Ladda hem

Vårt nyhetsbrev – Utvalda börsnyheter och heta investeringscase varje vecka

Prenumerera

Nyheter om Moberg Pharma

Läses av andra just nu

Innehåller annonslänkar

Så kommer du igång med trading

Här lyfter vi fram trading som utbildningstema, så att du som läsare ska få en möjlighet att fördjupa dig mer och spetsa dina kunskaper. Nedan finner du ett antal matiga guider och vi lyfter även fram vårt förstahandsval av mäklare och plattform: IG.